ArticleBioMed research international2020
EGFR-AS1 Promotes Bladder Cancer Progression by Upregulating EGFR.
Article in BioMed research international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 38 citations in OpenAlex.
- Mechanism of RBM15 in the Immune Escape of Non-small Cell Lung Cancer Cells Via the LncRNA EGFR-AS1/USP3/PD-L1 Axis.Biological procedures online · 2026Article
- LncRNA EGFR-AS1 inhibits ferroptosis to reduce radiosensitivity of cervical cancer through the m6A/IGF2BP3/APAF1 axis.BMC cancer · 2026Article
- Role of lncRNA TPRG1-AS1 in the development of cervical squamous cell carcinoma and its prognostic value.Discover oncology · 2024Article
- mir-605-3p prevents liver premetastatic niche formation by inhibiting angiogenesis via decreasing exosomal nos3 release in gastric cancer.Cancer cell international · 2024Article
- Clinical role of the long non‑coding RNA, EGFR‑AS1, in patients with cancer: A systematic review and meta‑analysis.Oncology letters · 2024Article
- Bladder cancer biomarkers: current approaches and future directions.Frontiers in oncology · 2024Review
- Targeted therapies in bladder cancer: signaling pathways, applications, and challenges.MedComm · 2023Review
- Article
- A promising new cancer marker: Long noncoding RNA EGFR-AS1.Frontiers in oncology · 2023Review
- Deciphering the Role of Melatonin-Related Signatures in Tumor Immunity and the Prognosis of Clear Cell Renal Cell Carcinoma.Oxidative medicine and cellular longevity · 2023Article
- A new thinking: deciphering the aberrance and clinical implication of copper-death signatures in clear cell renal cell carcinoma.Cell & bioscience · 2022Article
- Definition and verification of novel metastasis and recurrence related signatures of ccRCC: A multicohort study.Cancer innovation · 2022Article
- SBSN drives bladder cancer metastasis via EGFR/SRC/STAT3 signalling.British journal of cancer · 2022Article
- Functions of non-coding RNAs in regulating cancer drug targets.Acta biochimica et biophysica Sinica · 2022Review
- Hypoxia-induced long noncoding RNA NR2F1-AS1 maintains pancreatic cancer proliferation, migration, and invasion by activating the NR2F1/AKT/mTOR axis.Cell death & disease · 2022Article
- Exploration of the Immune-Related Long Noncoding RNA Prognostic Signature and Inflammatory Microenvironment for Cervical Cancer.Frontiers in pharmacology · 2022Article
- Progress in the Research and Targeted Therapy of ErbB/HER Receptors in Urothelial Bladder Cancer.Frontiers in molecular biosciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long noncoding RNAs play an essential role in bladder cancer progression. The role of long noncoding RNA EGFR-AS1 in bladder cancer needs further study. We used clinical specimens to analyze the relationship between EGFR-AS1 and bladder cancer patients' characteristics. The functional experiments and mechanism studies were performed using qRT-PCR, transwell assay, survival analysis, and correlation analysis. We found that high expression of EGFR-AS1 was nearly related to aggressive bladder cancer and indicated poor prognosis for patients. The functional experiments in vivo and in vitro suggested that EGFR-AS1 promoted the proliferation and invasion of bladder cancer cells. Mechanically, EGFR-AS1 promoted the expression of EGFR by inhibiting the degradation of EGFR mRNA, thereby promoting the metastasis of bladder cancer. In addition, EGFR-AS1/EGFR may be involved in the immune-related pathways of bladder cancer. These studies indicate that the EGFR-AS1/EGFR pathway may be a potential diagnostic marker and therapeutic target for bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.